LSV Asset Management grew its position in shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 20.1% in the 4th quarter, Holdings Channel reports. The firm owned 159,570 shares of the specialty pharmaceutical company’s stock after acquiring an additional 26,740 shares during the quarter. LSV Asset Management’s holdings in Jazz Pharmaceuticals were worth $21,486,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of JAZZ. Toronto Dominion Bank lifted its stake in shares of Jazz Pharmaceuticals by 12.4% in the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after acquiring an additional 81 shares during the last quarter. Advisor Group Inc. lifted its stake in shares of Jazz Pharmaceuticals by 62.4% in the 3rd quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock valued at $210,000 after acquiring an additional 550 shares during the last quarter. Intl Fcstone Inc. bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $230,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Jazz Pharmaceuticals by 795.4% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,746 shares of the specialty pharmaceutical company’s stock valued at $255,000 after acquiring an additional 1,551 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its stake in shares of Jazz Pharmaceuticals by 29.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 1,760 shares of the specialty pharmaceutical company’s stock valued at $257,000 after acquiring an additional 400 shares during the last quarter. 91.42% of the stock is owned by hedge funds and other institutional investors.
In other Jazz Pharmaceuticals news, SVP Iain Mcgill sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the transaction, the senior vice president now owns 28,383 shares in the company, valued at approximately $3,786,859.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Matthew P. Young sold 700 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $152.16, for a total value of $106,512.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,452 shares of company stock worth $2,985,885. 4.30% of the stock is owned by company insiders.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.40. Jazz Pharmaceuticals had a return on equity of 22.92% and a net margin of 23.58%. The company had revenue of $411.86 million for the quarter, compared to the consensus estimate of $420.67 million. equities analysts forecast that Jazz Pharmaceuticals plc – will post 9.76 earnings per share for the current year.
JAZZ has been the subject of a number of recent research reports. Wells Fargo & Co reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 25th. Cantor Fitzgerald reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Sunday, December 3rd. FBR & Co initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $206.00 target price for the company. Zacks Investment Research lowered Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $195.00 target price (down previously from $210.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seventeen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $179.44.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/02/09/jazz-pharmaceuticals-plc-jazz-shares-bought-by-lsv-asset-management.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc – (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.